# Plain Language Summary: Diane Powis Ovarian Cancer Testing Access Act

This bill makes sure that Medicare will pay for a specific type of blood test that helps doctors detect ovarian cancer. The test, called a multimarker test, looks for multiple warning signs of ovarian cancer in a patient's blood. Right now, Medicare doesn't automatically cover these tests, which means patients often have to pay out of pocket or fight with their insurance company to get coverage. This bill changes that by saying these tests are "reasonable and necessary"—the official language Medicare uses to decide what it will pay for.

The bill specifically applies to people who have already been diagnosed with an ovarian adnexal mass (an abnormal growth near the ovaries). If a doctor determines the test is needed for that patient and the test has been approved by the FDA, Medicare will cover it starting January 1, 2023. This matters because ovarian cancer is often caught late, and these multimarker tests can help doctors identify cancer earlier when treatment is more effective. By removing the financial barrier, the bill makes it easier for Medicare patients to get tested without worrying about whether they can afford it.

The practical impact is straightforward: Medicare beneficiaries who need this test won't have to choose between getting tested and paying their bills. Their doctors can order the test based on medical need rather than insurance coverage concerns. This is particularly important for older Americans on Medicare, who are at higher risk for ovarian cancer and may be living on fixed incomes.

Diane Powis Ovarian Cancer Testing Access Act

Dean, Madeleine

Diane Powis Ovarian Cancer Testing Access Act This bill provides for Medicare coverage of multimarker tests related to ovarian cancer (i.e., tests that evaluate more than one tumor marker with respect to ovarian cancer).